The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study
Open accessAbstract
Background & aims Non-alcoholic steatohepatitis (NASH) is a chronic, progressive fibrotic liver disease that can lead to cirrhosis. While liver biopsy is considered the reference standard for the histologic diagnosis of NASH and staging of fibrosis, its use in clinical practice is limited. Non-invasive tests (NITs) are increasingly being used to identify and stage liver fibrosis in patients with NASH, and several can assess liver-related outcomes. We report changes in various NITs in patients treated with obeticholic acid (OCA) or placebo in the phase III REGENERATE study.Methods Patients with NASH and fibrosis stage F2 or F3 (n = 931) were randomized (1:1:1) to receive placebo, OCA 10 mg, or OCA 25 mg once daily. Various NITs based on clinical chemistry and/or imaging were evaluated at baseline and throughout the study.Results Rapid, sustained reductions from baseline in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltransferase levels, as well as in Fibrosis-4 (FIB-4), FibroTest, FibroMeter, and FibroScan-AST scores were observed in OCA-treated vs. placebo-treated patients. Reduction in liver stiffness by vibration-controlled transient elastography was observed in the OCA 25 mg group vs. the placebo group at Month 18. NIT changes were associated with shifts in histologic fibrosis stage. The greatest improvements were observed in patients with ≥1-stage fibrosis improvement; however, improvements in ALT, AST, FIB-4, and FibroTest were also observed in OCA-treated patients whose histologic fibrosis remained stable.Conclusions Based on the REGENERATE Month 18 interim analysis, rapid and sustained improvements in various NITs were observed with OCA treatment. Dynamic changes in selected NITs separated histologic responders from non-responders. These results suggest that NITs may be useful in assessing histologic response to OCA therapy. CLINICALTRIALS.Gov number NCT02548351 LAY SUMMARY: Non-alcoholic steatohepatitis (NASH) is a chronic, progressive liver disease that can lead to cirrhosis. To diagnose and assess liver fibrosis (scarring) in patients with NASH, non-invasive tests (NITs) are increasingly being used rather than liver biopsy, which is invasive, expensive, and can be risky. In the REGENERATE study, which is evaluating the effects of obeticholic acid vs. placebo in patients with NASH, various NITs were also evaluated. This analysis shows that improvements in levels of certain blood components, as well as favorable results of ultrasound imaging and proprietary tests of liver function, were associated with improvements in liver fibrosis after treatment with obeticholic acid, suggesting that NITs may be useful alternatives to liver biopsy in assessing NASH patients' response to therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some improvements in NITs were related to the treatment arm but not per se to histological response, whereas others, e.g. VCTE or ELF, correlated better with changes in fi brosis stage regardless of the treatment arm, suggesting that they re fl ect histological changes regardless of a drug ' s mode of action.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [267]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some improvements in NITs were related to the treatment arm but not per se to histological response, whereas others, e.g. VCTE or ELF, correlated better with changes in fi brosis stage regardless of the treatment arm, suggesting that they re fl ect histological changes regardless of a drug ' s mode of action.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [267]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The most extensive analysis in that regard is from the REGENERATE trial of obeticholic acid, 267 which analysed NIT responses between histological responders and nonresponders.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [267]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,255
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Transient elastography: a new noninvasive method for assessment of hepatic fibrosis
Sandrin, L., Fourquet, B., Hasquenoph, J.-M., Yon, S., Fournier, C., Mal, F., Christidis, C., Ziol, M., Poulet, B., Kazemi, F., et al. (2003) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2003.07.001 · Cited by 2,734
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
Ratziu, V., Charlotte, F., Heurtier, A., Gombert, S., Giral, P., Bruckert, E., Grimaldi, A., Capron, F., & Poynard, T. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.084 · Cited by 2,106
Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
Self-citationComparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Shah, A. G., Lydecker, A. D., Murray, K. F., Tetri, B., Contos, M. J., & Sanyal, A. J. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.05.033 · Cited by 1,561
Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)33041-7 · Cited by 1,277
Self-citation
Cited by
Sorted by citations
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 545
Cusi, K. J., Abdelmalek, M. F., Apovian, C. M., Balapattabi, K., Bannuru, R. R., Barb, D., Bardsley, J. K., Beverly, E. A., Corbin, K. D., ElSayed, N. A., et al. (2025) · Diabetes Care · doi:10.2337/dci24-0094 · Cited by 417
Liver diseases: epidemiology, causes, trends and predictions
Gan, C., Yuan, Y., Shen, H., Gao, J., Kong, X., Che, Z., Guo, Y., Wang, H., Dong, E., & Xiao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02072-z · Cited by 416
Metabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki‐Järvinen, H., & Loomba, R. S. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 365
Lin, H., Lee, H. W., Yip, T. C.-F., Tsochatzis, E., Petta, S., Bugianesi, E., Yoneda, M., Zheng, M.-H., Hagström, H., Boursier, J., et al. (2024) · JAMA · doi:10.1001/jama.2024.1447 · Cited by 250
Self-citationWattacheril, J. J., Abdelmalek, M. F., Lim, J. K., & Sanyal, A. J. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.06.013 · Cited by 236
Impact of non-invasive biomarkers on hepatology practice: past, present and future
Anstee, Q. M., Castera, L., & Loomba, R. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.026 · Cited by 224
NAFLD and NASH: etiology, targets and emerging therapies
Wei, S., Wang, L., Evans, P. C., & Xu, S. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.103910 · Cited by 219
Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options
Grander, C., Grabherr, F., & Tilg, H. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad095 · Cited by 236
FXR agonists in NASH treatment
Adorini, L., & Trauner, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.034 · Cited by 200
Sterling, R. K., Patel, K., Duarte‐Rojo, A., Asrani, S. K., Alsawas, M., Dranoff, J. A., Fiel, M. I., Murad, M. H., Leung, D. H., Levine, D., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000845 · Cited by 188
Noninvasive assessment of liver fibrosis in NAFLD
Sanyal, A. J., Castera, L., & Wong, V. W.-S. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.03.042 · Cited by 157
Breakthroughs in therapies for NASH and remaining challenges
Ratziu, V., Francque, S., & Sanyal, A. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.002 · Cited by 132
Liver disease is a significant risk factor for cardiovascular outcomes – A UK Biobank study
Roca‐Fernández, A., Banerjee, R., Thomaides-Brears, H. B., Telford, A., Sanyal, A. J., Neubauer, S., Nichols, T. E., Raman, B., McCracken, C., Petersen, S. E., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.05.046 · Cited by 131
FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid
Wang, K., Zhang, Y., Wang, G., Hao, H., & Wang, H. (2023) · Medicinal Research Reviews · doi:10.1002/med.21991 · Cited by 126
Noninvasive Assessment of Liver Fibrosis
Castéra, L., Rinella, M. E., & Tsochatzis, E. A. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2403308 · Cited by 120
Huang, S., & Liu, C. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0422 · Cited by 108
NASH drug treatment development: challenges and lessons
Tilg, H., Byrne, C. D., & Targher, G. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00159-0 · Cited by 81
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Kokkorakis, M., Muzurović, E. M., Volčanšek, Š., Chakhtoura, M., Hill, M. A., Mikhailidis, D. P., & Mantzoros, C. S. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001087 · Cited by 79
Zhou, S., You, H., Qiu, S., Yu, D., Bai, Y., He, J., Cao, H., Che, Q., Guo, J., & Su, Z. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113577 · Cited by 71
Gidener, T., Dierkhising, R. A., Mara, K. C., Therneau, T. M., Venkatesh, S. K., Ehman, R. L., Yin, M., & Allen, A. M. (2023) · Hepatology · doi:10.1002/hep.32594 · Cited by 62
Díaz, L. A., Arab, J. P., Idalsoaga, F. J., Perelli, J., Vega, J. A., Dirchwolf, M., Carreño, J., Samith, B., Valério, C. M., Moreira, R. O., et al. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.101903 · Cited by 72
Kim, M. N., Han, J. W., An, J., Kim, B. K., Jin, Y., Kim, S., Lee, M., Lee, H. A., Cho, Y., Kim, H. Y., et al. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0506 · Cited by 65
Motta, B. M., Masarone, M., Torre, P., & Persico, M. (2023) · Cancers · doi:10.3390/cancers15225458 · Cited by 61
The Role of Nuclear Receptors in the Pathogenesis and Treatment of Non-alcoholic Fatty Liver Disease
Yang, Z., Danzeng, A., Liu, Q., Zeng, C., Xu, L., Mo, J., Ciren, P., Wang, X., Wang, C., Zhang, B., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.87305 · Cited by 61
Abdelmalek, M. F., Suzuki, A., Sanchez, W., Lawitz, E., FILOZOF, C. M., Cho, H.-J., Baek, E., Choi, J., & Baek, S. J. (2023) · Contemporary Clinical Trials · doi:10.1016/j.cct.2023.107176 · Cited by 56
MASLD treatment—a shift in the paradigm is imminent
Machado, M. V. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1316284 · Cited by 51
MASH clinical trials and drugs pipeline: An impending tsunami
Noureddin, M. (2024) · Hepatology · doi:10.1097/hep.0000000000000860 · Cited by 54
Recent Advancements in Antifibrotic Therapies for Regression of Liver Fibrosis
Jangra, A., Kothari, A., Sarma, P., Medhi, B., Omar, B. J., & Kaushal, K. (2022) · Cells · doi:10.3390/cells11091500 · Cited by 48
Circadian Regulation of Gene Expression and Metabolism in the Liver
Guan, D., & Lazar, M. A. (2022) · Seminars in Liver Disease · doi:10.1055/a-1792-4240 · Cited by 48
Azizsoltani, A., Hatami, B., Zali, M. R., Mahdavi, V., Baghaei, K., & Alizadeh, E. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115777 · Cited by 40
Tantu, M. T., Farhana, F. Z., Haque, F., Koo, K. M., Qiao, L., Ross, A. G., & Shiddiky, M. J. A. (2025) · npj gut and liver. · doi:10.1038/s44355-025-00030-2 · Cited by 45
Borisov, A. N., Kutz, A., Christ, E., Heim, M. H., & Ebrahimi, F. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad249 · Cited by 37
Brown, E. A., Minnich, A., Sanyal, A. J., Loomba, R. S., Du, S., Schwarz, J., Ehman, R. L., Karsdal, M. A., Leeming, D. J., Cizza, G., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2022.100661 · Cited by 37
Wong, V. W., Anstee, Q. M., Nitze, L. M., Geerts, A. M., George, J., Nolasco, V., Kjær, M. S., Ladelund, S., Newsome, P. N., & Ratziu, V. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102310 · Cited by 39
Theofilis, P., Vordoni, A., & Kalaitzidis, R. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i39.5691 · Cited by 40
Marchianò, S., Biagioli, M., Morretta, E., Giorgio, C. D., Roselli, R., Bordoni, M., Bellini, R., Urbani, G., Massa, C., Monti, M. C., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-28647-4 · Cited by 37
Zhou, X., Li, Y., Kim, S. U., Yip, T. C., Petta, S., Nakajima, A., Tsochatzis, E. A., Shi, J., Chan, W., Boursier, J., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.07.011 · Cited by 36
The contribution of the gut-liver axis to the immune signaling pathway of NAFLD
Liu, J., Wu, A., Cai, J., She, Z., & Li, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.968799 · Cited by 42
Liu, Y., Liu, T., Zhao, X. M., & Gao, Y. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04509-6 · Cited by 34
MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials
Zannad, F. M., Sanyal, A. J., Butler, J., Ferreira, J. P., Girerd, N., Miller, V., Pandey, A., Parikh, C. R., Ratziu, V., Younossi, Z. M., et al. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13793 · Cited by 38
Wang, Y., Song, S. J., Jiang, Y., Lai, J. C., Wong, G. L., Wong, V. W., & Yip, T. C. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0246 · Cited by 32
Kamada, Y., Nakamura, T., Isobe, S., Hosono, K., Suama, Y., Ohtakaki, Y., Nauchi, A., Yasuda, N., Mitsuta, S., Miura, K., et al. (2022) · Journal of Gastroenterology · doi:10.1007/s00535-022-01932-1 · Cited by 31
Puengel, T., & Tacke, F. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2374463 · Cited by 33
Potential therapeutic strategies for MASH: from preclinical to clinical development
Xie, Z., Li, Y., Cheng, L., Huang, Y., Rao, W., Shi, H., & Li, J. (2024) · Life Metabolism · doi:10.1093/lifemeta/loae029 · Cited by 31
Hu, Y., Sun, C., Chen, Y., Liu, Y., & Fan, J. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00123 · Cited by 34
Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD
Vitulo, M., Gnodi, E., Rosini, G., Meneveri, R., Giovannoni, R., & Barisani, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612748 · Cited by 36
Mao, Q., Lin, B., Zhang, W., Zhang, Y., Zhang, Y., Cao, Q., & Xu, M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1371574 · Cited by 29
Suresh, M. G., Mohamed, S., Geetha, H. S., Prabhu, S., Trivedi, N., Ng, Z. C., Mehta, P. D., Brar, A. S., Sohal, A., Goyal, M. K., et al. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i2.113149 · Cited by 30
Yue, C., Li, D., Fan, S., Tao, F., Yu, Y., Lü, W., Chen, Q., Yuan, A., Wu, J., Zhao, G., et al. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122291 · Cited by 30
Ktenopoulos, N., Sagris, Μ., Gerogianni, M., Pamporis, K., Apostolos, A., Balampanis, K., Tsioufis, K. P., Toutouzas, K. P., & Tousoulis, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910595 · Cited by 27
Kaylan, K. B., & Paul, S. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01558-y · Cited by 27
Farnesoid X receptor: From Structure to Function and Its Pharmacology in Liver Fibrosis
Ding, C., Wang, Z., Dou, X., Yang, Q., Ning, Y., Kao, S., Sang, X., Hao, M., Wang, K., Peng, M., et al. (2023) · Aging and Disease · doi:10.14336/ad.2023.0830 · Cited by 29
Diagnosis and non‐invasive assessment of MASLD in type 2 diabetes and obesity
Chan, W., Petta, S., Noureddin, M., Goh, G. B., & Wong, V. W. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17866 · Cited by 25
ROS-responsive nanoparticle delivery of obeticholic acid mitigate primary sclerosing cholangitis
Yao, Q., Wang, B., Yu, J., Pan, Q., Yu, Y., Feng, X., Chen, W., Yang, J., Gao, C., & Cao, H. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.08.006 · Cited by 24
MAFLD in adults: non-invasive tests for diagnosis and monitoring of MAFLD
Chan, W., Wong, V. W., Adams, L. A., & Nguyen, M. H. (2024) · Hepatology International · doi:10.1007/s12072-024-10661-x · Cited by 24
Monitoring disease progression in metabolic dysfunction‐associated steatotic liver disease
Noureddin, N., Copur‐Dahi, N., & Loomba, R. S. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17752 · Cited by 25
Jirapinyo, P., Zucker, S. D., & Thompson, C. C. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002087 · Cited by 23
Gao, Y., Lin, J., Ye, C., Guo, S., & Jiang, C. (2023) · Liver Research · doi:10.1016/j.livres.2023.09.002 · Cited by 26
Stoess, C., Leszczynska, A., Kui, L., & Feldstein, A. E. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1218807 · Cited by 24
The emerging significance of mitochondrial targeted strategies in NAFLD treatment
Zhang, T., Nie, Y., & Wang, J. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121943 · Cited by 21
Amorim, R., Soares, P., Chavarria, D., Benfeito, S., Cagide, F., Teixeira, J., Oliveira, P. J., & Borges, F. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116723 · Cited by 21
Jia, X., Song, E., Liu, Y., Chen, J., Wan, P., Hu, Y., Ye, D., Chakrabarti, S., Mahajan, H., George, J., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101257 · Cited by 20
Combination Therapy of Endoscopic Gastric Remodeling with GLP-1RA for the Treatment of MASLD
Jirapinyo, P., Jaroenlapnopparat, A., Zucker, S. D., & Thompson, C. C. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07178-5 · Cited by 20
Sanyal, A. J., Loomba, R. S., Anstee, Q. M., Ratziu, V., Kowdley, K. V., Rinella, M. E., Harrison, S. A., Resnick, M. B., Capozza, T. A., Sawhney, S., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000325 · Cited by 19
Therapeutic Targets and Approaches to Manage Inflammation of NAFLD
Geng, W., Liao, W., Cao, X., & Yang, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13020393 · Cited by 20
Research Priorities for Precision Medicine in NAFLD
Iruzubieta, P., Bataller, R. A., Arias, M., Arrese, M. A., Calleja, J. L., Castro‐Narro, G., Cusi, K. J., Dillon, J. F., Martínez‐Chantar, M. L., Mateo, M., et al. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.016 · Cited by 18
Xu, M., Tan, J., Zhu, L., Ge, C., Zhang, Y., Gao, F., Dai, X., Kuang, Q., Chai, J., Zou, B., et al. (2023) · Advanced Science · doi:10.1002/advs.202302130 · Cited by 20
Insights into the gut-liver axis: mechanisms and emerging therapies in hepatocellular carcinoma
Hu, Y., Gao, M., Chenghuang, J., & Bao, R. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1595853 · Cited by 16
Diagnosis and assessment of disease severity in patients with nonalcoholic fatty liver disease
Li, J., Delamarre, A., Wong, V. W., & de Lédinghen, V. (2023) · United European Gastroenterology Journal · doi:10.1002/ueg2.12491 · Cited by 15
Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom
Knezović, E., Hefer, M., Blažanović, S., Petrović, A., Tomičić, V., Srb, N., Kirner, D., Smolić, R., & Smolić, M. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47030154 · Cited by 16
Jang, H.-J., Han, N., Staatz, C. E., Kwak, J., & Baek, I. (2023) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2023.102227 · Cited by 15
Chen, C., Zhang, B., Tu, J., Peng, Y., Zhou, Y., Yang, X., Yu, Q.-M., & Tan, X. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115992 · Cited by 16
Obesity and Metabolic Dysfunction-associated Fatty Liver Disease: Understanding the Intricate Link
Vulchi, J., Suryadevara, V., Mohan, P., Kamalanathan, S., Sahoo, J., Naik, D., & Selvarajan, S. (2023) · Journal of Translational Gastroenterology · doi:10.14218/jtg.2023.00043 · Cited by 18
Noninvasive assessment of liver fibrosis and portal hypertension
Duarte‐Rojo, A., Patel, K., & Rockey, D. C. (2024) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001019 · Cited by 16
Kawaguchi, T., Murotani, K., Kajiyama, H., Obara, H., Yamaguchi, H., Toyofuku, Y., Kaneko, F., Seino, Y., & Uchida, S. (2024) · Journal of Gastroenterology · doi:10.1007/s00535-024-02122-x · Cited by 17
Targeting Metabolism: Innovative Therapies for MASLD Unveiled
Wang, W., Gao, X., Niu, W., Yin, J., & He, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094077 · Cited by 14
Therapeutic developments in metabolic dysfunction-associated fatty liver disease
Shi, Y., & Fan, J. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002091 · Cited by 14
Update on Clinical Trials for Nonalcoholic Steatohepatitis.
Nathani, R. R., & Bansal, M. B. (2023) · PubMed Central · Cited by 13
Amoroso, M., Augustín, S., Moosmang, S., & Gashaw, I. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02448-2 · Cited by 15
Nonalcoholic Fatty Liver Disease
Sanyal, A. J., Natta, M. L. V., & Tonascia, J. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2118255 · Cited by 13
Bile acids in metabolic dysfunction-associated steatotic liver disease
Zerem, E., Kunosić, S., Kurtčehajić, A., Zerem, D., & Zerem, O. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i8.108606 · Cited by 12
The discovery of 12β-methyl-17-epi-18-nor-bile acids as potent and selective TGR5 agonists
Luxenburger, A., Harris, L. D., Ure, E. M., Jiao, W., Woolhouse, A. D., Cameron, S. A., Weymouth‐Wilson, A., Furneaux, R. H., Pitman, J. L., & Hinkley, S. F. R. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115143 · Cited by 12
Analytical performance of the Enhanced Liver Fibrosis (ELF) Test on the Atellica IM Analyzer
Palladino, A., Gee, M. F. W., Shalhoub, V., & Kiaei, D. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117461 · Cited by 12
Jirapinyo, P., Thompson, C. C., García–Tsao, G., Zucker, S. D., & Ryou, M. K. (2023) · Endoscopy · doi:10.1055/a-2146-8857 · Cited by 12
Sumida, Y., Toyoda, H., Yasuda, S., Kimoto, S., Sakamoto, K., Nakade, Y., Ito, K., Osonoi, T., & Yoneda, M. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64896 · Cited by 13
Tincopa, M. A., & Loomba, R. S. (2024) · Seminars in Liver Disease · doi:10.1055/s-0044-1788277 · Cited by 12
Sanyal, A. J., Nakajima, A., Bugianesi, E., Sebastiani, G., Schattenberg, J. M., Adams, L. A., Noureddin, M., Yoneda, M., Bédossa, P., Younossi, Z. M., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.12.001 · Cited by 11
Prevention of liver cancer in the era of next-generation antivirals and obesity epidemic
Suzuki, H., Fujiwara, N., Singal, A. G., Baumert, T. F., Chung, R. T., Kawaguchi, T., & Hoshida, Y. (2025) · Hepatology · doi:10.1097/hep.0000000000001227 · Cited by 11
Ability of soluble TREM2 and PRO-C3 as biomarkers to predict changes in MASLD activity
Wernberg, C. W., Chandran, V. I., Lauridsen, M. M., Skytthe, M. K., Hansen, C. D., Hansen, J. K., Grønkjær, L. L., Jacobsen, B. G., Caterino, T. D., Detlefsen, S., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101432 · Cited by 13
Non-Invasive Detection of Fibrotic NASH in NAFLD Patients with Low or Intermediate FIB-4
John, K., Franck, M., Aoua, S. A., Rau, M., Huber, Y., Schattenberg, J. M., Geier, A., Bahr, M. J., Wedemeyer, H. H., Schulze‐Osthoff, K., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154394 · Cited by 11
Majeed, M. A., Nagabhushanam, K., Noureddin, M., Paulose, S., Barik, C., Saklecha, S., & Mundkur, L. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1201186 · Cited by 10
Therapeutic Role of Polyphenol Extract from Prunus cerasifera Ehrhart on Non-Alcoholic Fatty Liver
Ren, J., Zhang, X., Perhat, S. H., Yang, P., Han, H., Li, Y., Gao, J., He, E., & Li, Y. (2024) · Plants · doi:10.3390/plants13020288 · Cited by 10
Bhattacharya, I., Maity, D. K., Kumar, A., Sarkar, S., Bhattacharya, T., Sahu, A., Sreedhar, R., & Arumugam, S. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04257-x · Cited by 11
Muñoz‐Espinosa, L. E., Torre, A., Cisneros, L., Montalvo, I., Malé, R., Mejía, S., Aguilar, J. R., Lizardi, J., Zuñiga‐Noriega, J., Eugenia Icaza, M., et al. (2025) · Liver International · doi:10.1111/liv.70131 · Cited by 10
Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice
Liu, S.-Y., Huang, C., Yang, Y., Huang, S., Lee, T.-Y., Li, T., Hou, M., & Lin, H. (2022) · PLoS ONE · doi:10.1371/journal.pone.0276717 · Cited by 10
Adorini, L., Rigbolt, K. T. G., Feigh, M., Roth, J. D., & Erickson, M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0300809 · Cited by 10
Das, S., Agarwal, K., Kapoor, N., Lakhani, O., & Gupta, A. D. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000935 · Cited by 10
Metadata
- Authors
- Rinella, M. E., Dufour, J.-F., Anstee, Q. M., Goodman, Z., Younossi, Z., Harrison, S. A., Loomba, R., Sanyal, A. J., Bonacci, M., Trylesinski, A., Natha, M., Shringarpure, R., Granston, T., Venugopal, A., & Ratziu, V.
- Affiliations
- Northwestern University (US)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Inova Health System (US)
- Pinnacle Clinical Research (US)
- University of California San Diego (US)
- Virginia Commonwealth University (US)
- Intercept Pharmaceuticals (United States) (US)
- Inserm (FR)
- Corresponding author
- Ratziu, Vlad
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2022-03
- Volume
- 76
- Issue
- 3
- Pages
- 536-548
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W3208671080
- Cited by
- 164
- References
- 45
- Citations by year
- 2026: 20 · 2025: 35 · 2024: 46 · 2023: 43 · 2022: 20
- FWCI
- 19.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Hepatology (acceptedVersion)
- PubMed (publishedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, cc-by-nc-nd)
- Open Access CRIS of the University of Bern
- Funders
- Intercept Pharmaceuticals
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- nonalcoholic steatohepatitis, obeticholic acid, liver fibrosis, non-invasive tests, treatment response, vibration-controlled transient elastography, FIB-4, FibroTest, FibroMeter, liver stiffness, alanine aminotransferase, histological response, fibrosis regression, liver cirrhosis
- MeSH terms
- Adult, Aged, Chenodeoxycholic Acid, Double-Blind Method, Female, Humans, Liver, Liver Cirrhosis, Liver Function Tests, Male, Middle Aged, Placebos, Logistic Models, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
